Washington Research Foundation

Viata offers hotel booking and comparative pricing for users.

Pacific Northwest Research Institute is a research institute for genetics and bioinformatics research.

Monod Bio is a life sciences company based in Seattle, Washington, focused on developing innovative biosensors for detecting proteins, toxins, antibodies, and other analytes. Founded in 2021, the company has created a biosensor platform that integrates binding, transduction, and amplification processes in a single step, allowing for the rapid and sensitive detection of a diverse array of target molecules. By leveraging recent advancements in computational protein engineering, Monod Bio has designed highly modular bio-sensing nanoswitches that facilitate cost-effective analytical assays. This technology aims to enhance the capabilities of the healthcare industry in biotechnology and medicine.

SEngine Precision Medicine, Inc. is a Seattle-based company that specializes in personalized cancer treatments through innovative technology. Founded in 2015, the company utilizes a proprietary search engine that combines functional genomics with robotic testing of cancer drugs on live patient organoids. This approach allows for the simultaneous testing of over 200 drugs against a patient’s unique tumor organoid, providing insights into the most effective and least toxic treatment options that traditional DNA sequencing may not reveal. By leveraging anonymized test results, SEngine not only empowers patients and oncologists with tailored treatment options but also aids in the development of new cancer-fighting drugs, positioning itself as a leader in the next generation of oncology diagnostics.

Cyrus Biotechnology, Inc. is a Seattle-based company that specializes in developing advanced software for protein structure prediction and design. Founded in 2014, it offers several key products, including Rosetta, a tool designed to create biologically active proteins for various medical applications such as treating brain cancer and addressing Celiac Disease. The company also provides Cyrus Bench, an enterprise version of Rosetta that includes a comprehensive suite of bio-molecular computation tools. Additionally, Cyrus Biotechnology offers specialized services like Cyrus CryoEM, which focuses on structure refinement and model building for complex biomolecular structures. Its innovative software solutions cater to pharmaceutical companies, biotech firms, and startups engaged in discovering therapeutics and developing novel consumer products.

Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety. It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacy and safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.

AdaptX is a healthcare data analytics and AI company that specializes in enhancing clinical and workflow outcomes for hospitals and surgery centers. Founded in Seattle in 2016 as a spin-off from Seattle Children's Hospital, AdaptX provides a platform that enables medical leaders and clinicians to access and analyze clinical data effectively. The platform integrates algorithms with existing electronic data systems, allowing healthcare providers to monitor performance, compare treatment approaches, and define patient cohorts. Through automated analytics, AdaptX helps healthcare service providers improve the quality and safety of care while also reducing costs.

Medcurity, Inc. is a company based in Spokane, Washington, that specializes in providing a HIPAA compliance platform tailored for healthcare systems. Founded in 2018, Medcurity offers a compliance management platform that helps healthcare organizations navigate complex HIPAA and security requirements. The platform features an intuitive interface that includes comprehensive surveys supporting multiple users and devices, along with an online action item tracking dashboard. This enables healthcare professionals to conduct risk assessments effectively, with integrated guidance to simplify the process of building or enhancing their HIPAA privacy and security programs.

A-Alpha Bio, Inc. is a biotechnology company based in Seattle, Washington, established in 2017. The company specializes in synthetic biology, offering a platform known as AlphaSeq, which assists pharmaceutical companies in the development of drugs that interact with multiple targets. A-Alpha Bio provides cell-based tools for high-throughput and quantitative measurements of protein interactions, facilitating target discovery, library screening, and preclinical drug characterization. Its proprietary technology enables the mapping of protein-protein interactions at a large scale, allowing for the identification and quantification of interactions among thousands of protein pairs simultaneously. By delivering detailed maps of these interactions, A-Alpha Bio helps researchers identify potential drug targets and understand disease mechanisms, thereby streamlining the therapeutic discovery process and improving the efficiency of drug development. The company comprises a team of experts in synthetic biology, structural biology, and next-generation sequencing, focused on overcoming challenges in the drug development pipeline.

AdaptX is a healthcare data analytics and AI company that specializes in enhancing clinical and workflow outcomes for hospitals and surgery centers. Founded in Seattle in 2016 as a spin-off from Seattle Children's Hospital, AdaptX provides a platform that enables medical leaders and clinicians to access and analyze clinical data effectively. The platform integrates algorithms with existing electronic data systems, allowing healthcare providers to monitor performance, compare treatment approaches, and define patient cohorts. Through automated analytics, AdaptX helps healthcare service providers improve the quality and safety of care while also reducing costs.

Absci is a drug and target discovery company that leverages deep learning AI and synthetic biology to enhance the therapeutic potential of proteins. Its Integrated Drug Creation Platform streamlines the process of identifying novel drug targets, discovering optimal biotherapeutic candidates, and generating the necessary cell lines for manufacturing. By combining biologic drug discovery and cell line development into a single, efficient workflow, Absci collaborates with biotech and pharmaceutical innovators to develop next-generation protein-based drugs. These innovations include Bionic Proteins, which feature nonstandard amino acids, and other unique drug designs that may be unattainable through conventional methods. Absci's mission is to facilitate the development of improved medicines by effectively translating innovative ideas into viable drugs.

Phase Genomics, Inc. is a biotechnology company based in Seattle, Washington, founded in 2015. The company specializes in developing innovative technology for genome assembly and metagenome deconvolution, focusing on its ProxiMeta Hi-C platform. This platform empowers researchers in various fields, including agriculture, human health, and industrial biology, by enabling the cultivation-independent assembly of bacterial genomes. By exploiting the structure of DNA, Phase Genomics aims to provide scientists with the most complete and accurate genomes and metagenomes possible, facilitating transformative discoveries and advancements in their respective areas of study.

Phytelligence, Inc. is an agricultural biotechnology company that specializes in growing and providing high-quality plants and innovative solutions for growers, nurseries, and horticultural experts. Founded in 2012 and based in Pullman, Washington, the company offers a range of tissue-cultured plantlets, including varieties of pear, apple, cherry, grape, and strawberry, all free from diseases, viruses, and pests. Phytelligence also provides custom genetic analysis services to evaluate the genetic similarities and differences among closely related plant samples. Its advanced propagation and quality control processes ensure that clients receive genetically confirmed plants that are healthy and ready for planting, ultimately enhancing productivity and quality in crop production.

Rodeo Therapeutics Corp. is a drug development company based in Seattle, Washington, focused on creating novel small molecule therapies aimed at treating inflammatory bowel disease and enhancing blood cell reconstitution after bone marrow transplants. Founded in 2017, the company specializes in targeting specific enzymes and biological pathways that are vital for tissue repair and regeneration. Its therapies work by increasing tissue levels of prostaglandin PGE2 through the inhibition of a prostaglandin-degrading enzyme, thereby facilitating tissue regeneration and protecting against conditions such as colitis. Rodeo Therapeutics is dedicated to advancing treatments that improve patient outcomes in various medical conditions related to tissue damage and recovery.

Arzeda Corporation is a synthetic biology company based in Seattle, Washington, that specializes in the development and manufacture of proteins and enzymes for various applications, including pharmaceuticals, polymers, and industrial chemicals. Founded in 2008, Arzeda utilizes advanced technology that combines physics-based protein design with artificial intelligence algorithms to create and validate new designer proteins and enzymes. The company aims to provide innovative solutions that offer competitive performance, cost efficiency, and sustainability, addressing the needs of clients in diverse industries.

WiBotic Inc. specializes in wireless charging and power optimization solutions primarily for robotic systems, including aerial, mobile, and underwater vehicles. Founded in 2014 and based in Seattle, the company offers a range of products such as wireless charging systems, onboard chargers, transmitters, antenna coils, and integrated options. Additionally, WiBotic provides battery intelligence and fleet management software designed to enhance the operational efficiency of robotic fleets, maximizing battery life and reducing charging and maintenance costs. Its technology enables automatic detection of robots or drones, facilitating seamless charging as they approach the wireless platform. WiBotic's solutions are characterized by their safety, reliability, scalability, and ease of implementation, making them suitable for various industrial applications.

HyperSciences, Inc. develops advanced drilling solutions for various applications, including energy, tunneling, transportation, and aerospace. Founded in 2014 and headquartered in Spokane, Washington, with an additional office in Austin, Texas, the company offers innovative technologies such as HyperDrill, which enhances the rate of penetration in oil, gas, and geothermal drilling by up to ten times compared to conventional methods. HyperSciences also provides a geothermal solution that utilizes HyperDrill to access deep geothermal energy deposits and the HyperBreaker, a rock-breaking solution designed for construction, mining, and tunneling. By employing low-cost chemical energy to propel projectiles to hypersonic speeds, the company's technology enables faster and deeper penetration into hard rock, effectively addressing challenges in drilling and tunneling operations.

ApoGen Biotechnologies, Inc., founded in 2014 and located in Seattle, Washington, is dedicated to developing innovative therapeutics aimed at addressing the challenges of cancer treatment, particularly the issue of drug resistance. The company focuses on targeting the key drivers of genomic mutations in cancer cells, which are central to tumor evolution and the development of resistance to existing therapies. By addressing the chronic mutations in cancer genomes, ApoGen aims to improve treatment efficacy, reduce cancer recurrence and metastasis, and enhance overall patient survival. The company's approach represents a shift from traditional therapies, providing new hope in the ongoing battle against cancer.

Nexgenia, Inc. is a biotechnology company based in Seattle, Washington, established in 2011. The company specializes in the development and manufacture of proprietary stimuli-responsive polymers and polymer-containing magnetic nanoparticles. These innovative materials are designed to change their state in response to minor environmental changes such as temperature, pH, and salt concentration. This unique characteristic allows Nexgenia's polymers to be combined with various chemicals and biological agents, enabling efficient molecular and cellular separations. As a result, the company's products enhance the speed, efficiency, and sensitivity of diagnostic tests and immunoassays, providing quicker results for medical professionals.

AAVogen is a biotech startup that develops gene therapeutics for muscle wasting diseases. This includes muscular dystrophy, inflammatory myopathies and cancer cachexia. We make you stronger.

AnswerDash, Inc. is a Seattle-based company that offers a cloud-based Q&A platform designed to provide contextual answers to customers on websites, web applications, and mobile experiences. Founded in 2012 and originally known as Qazzow, Inc., the company allows businesses to integrate self-service features that enable customers to obtain answers through a point-and-click interface, facilitating easy access to information without cluttering web pages. By predicting user questions based on the content of the page, AnswerDash helps reduce support costs and enhances customer engagement. The platform can also integrate with live chat services to offer personalized assistance. As of June 2020, AnswerDash operates as a subsidiary of CloudEngage, Inc.

Faraday Pharmaceuticals, Inc. is a biopharmaceutical company based in Seattle, Washington, that focuses on developing innovative therapies to treat ischemia-reperfusion injury, particularly following ST elevation myocardial infarction. Founded in 2014, the company has in-licensed proprietary liquid formulations of reduced nonmetal gaseous elements, which were developed in the laboratory of Dr. Mark Roth at the Fred Hutchinson Cancer Center. Faraday's therapeutics aim to utilize specific reduced forms of elements to enhance patient outcomes, providing medical practitioners with effective treatment options for ischemia-reperfusion injury and other critical care conditions.

C-SATS provides a personalized surgical skills assessment platform using a unique combination of data analytics, artificial intelligence. It specializes in the fields of robotic surgery, surgical skills, surgical insights, laparoscopic surgery, and minimally invasive surgery. The company was founded in 2014 and headquartered in Seattle, Washington.

Cardeas Pharma is focused on developing a novel antibiotic formulation that combines two drugs to effectively target highly resistant Gram-negative bacteria, such as Pseudomonas aeruginosa and Acinetobacter baumannii, as well as carbapenem-resistant Enterobacteriaceae. This formulation is also effective against biofilms and Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). The antibiotics are delivered through a single-patient use nebulizer that produces small, uniform aerosol droplets, allowing for targeted delivery to the small airways and alveoli. By integrating this innovative antibiotic formulation with advanced drug-delivery technology, Cardeas Pharma aims to improve clinical outcomes for patients suffering from serious, hospital-acquired respiratory infections.

Faraday Pharmaceuticals, Inc. is a biopharmaceutical company based in Seattle, Washington, that focuses on developing innovative therapies to treat ischemia-reperfusion injury, particularly following ST elevation myocardial infarction. Founded in 2014, the company has in-licensed proprietary liquid formulations of reduced nonmetal gaseous elements, which were developed in the laboratory of Dr. Mark Roth at the Fred Hutchinson Cancer Center. Faraday's therapeutics aim to utilize specific reduced forms of elements to enhance patient outcomes, providing medical practitioners with effective treatment options for ischemia-reperfusion injury and other critical care conditions.

FlexMinder, Inc. is a Seattle-based company that develops enterprise software solutions aimed at private health exchanges, health carriers, and third-party administrators (TPAs). Founded in 2011, FlexMinder focuses on automating the healthcare reimbursement process, enhancing the management of medical spending for flexible spending accounts. The company aggregates healthcare information from various sources to streamline claims submission, significantly reducing manual processing time and costs for TPAs. By providing online tools for managing the reimbursement process, FlexMinder aims to improve the user experience for consumers utilizing their flexible spending arrangements. In 2013, the company secured $1.4 million in Series AA financing to support its growth initiatives and was selected for the TechStars incubator program. As of January 2017, FlexMinder operates as a subsidiary of Jelleyvision Lab Inc.

Skytap, Inc. specializes in providing cloud-based development and testing environments aimed at migrating and modernizing enterprise applications globally. The company's primary offering, Skytap Cloud, allows for self-service access to production-like environments, facilitating more frequent code testing for development and testing teams. Skytap’s platform supports organizations in transitioning to modern software delivery methods by enabling the rapid migration of traditional workloads to the cloud and fostering the adoption of agile and DevOps practices. This approach helps businesses enhance their application development efficiency and integrate new cloud architectures. Additionally, Skytap provides a range of services including cloud migration, application modernization, training, and strategic consulting. Founded in 2006 and headquartered in Seattle, Washington, Skytap also maintains locations in Toronto, Canada, and London, United Kingdom.

AnswerDash, Inc. is a Seattle-based company that offers a cloud-based Q&A platform designed to provide contextual answers to customers on websites, web applications, and mobile experiences. Founded in 2012 and originally known as Qazzow, Inc., the company allows businesses to integrate self-service features that enable customers to obtain answers through a point-and-click interface, facilitating easy access to information without cluttering web pages. By predicting user questions based on the content of the page, AnswerDash helps reduce support costs and enhances customer engagement. The platform can also integrate with live chat services to offer personalized assistance. As of June 2020, AnswerDash operates as a subsidiary of CloudEngage, Inc.

FlexMinder, Inc. is a Seattle-based company that develops enterprise software solutions aimed at private health exchanges, health carriers, and third-party administrators (TPAs). Founded in 2011, FlexMinder focuses on automating the healthcare reimbursement process, enhancing the management of medical spending for flexible spending accounts. The company aggregates healthcare information from various sources to streamline claims submission, significantly reducing manual processing time and costs for TPAs. By providing online tools for managing the reimbursement process, FlexMinder aims to improve the user experience for consumers utilizing their flexible spending arrangements. In 2013, the company secured $1.4 million in Series AA financing to support its growth initiatives and was selected for the TechStars incubator program. As of January 2017, FlexMinder operates as a subsidiary of Jelleyvision Lab Inc.

Resolve Therapeutics, LLC is a clinical-stage biopharmaceutical company based in Seattle, Washington, focused on developing innovative therapies for autoimmune diseases, particularly systemic lupus erythematosus and Sjögren's syndrome. Established in 2010, the company is advancing its lead biologic compounds, including RSLV-132, a mono-specific nuclease Fc-fusion protein designed to target and eliminate immune complexes, thereby reducing kidney damage and interferon activation. Additionally, Resolve Therapeutics is progressing RSLV-133, a bi-specific Fc-nuclease fusion protein that integrates dual nuclease activities into a single therapeutic molecule. The company's research is rooted in significant discoveries made by Dr. Keith Elkon and Dr. Jeff Ledbetter at the University of Washington School of Medicine, with a commitment to enhancing the quality of life for patients affected by these challenging conditions.

Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutic antibodies to improve treatment for migraine patients in the United States, Australia, and Ireland. The company's lead candidate, eptinezumab, is a monoclonal antibody targeting calcitonin gene-related peptide, currently in late-stage clinical development for migraine prevention. Alder is also developing ALD1910, a preclinical monoclonal antibody aimed at inhibiting pituitary adenylate cyclase-activating polypeptide-38 for similar purposes, and Clazakizumab, which targets the pro-inflammatory cytokine interleukin-6 and has completed two Phase 2b trials. In addition to its product development efforts, Alder engages in strategic collaborations, notably with CSL Limited for advancing clazakizumab as a treatment for solid organ transplant rejection. Incorporated in 2002 and headquartered in Bothell, Washington, Alder operates primarily in the United States, where it generates most of its revenue.

Uptake Medical specializes in developing innovative medical technologies aimed at treating lung diseases. The company's flagship product, InterVapor™, is an endoscopic lung volume reduction therapy designed specifically for individuals with severe emphysema. This unique approach leverages the body’s natural healing processes and does not introduce any foreign materials into the lungs. Clinical studies have shown that InterVapor™ can lead to significant improvements in patients' breathing function, exercise capacity, and overall quality of life.

Groove Biopharma focuses on the generation of novel microRNA (miRNA) therapeutics with improved properties, including higher potency and enhanced pharmacodynamic activity. Endogenous microRNAs (miRNAs) are involved in extensive regulatory networks for many target genes and pathways. Groove Biopharma’s core technology addresses a new avenue of nucleotide therapeutic drug discovery via modulation of cellular miRNA. Using exclusive technology, Groove Biopharma is generating a series of lead candidates with the potential to be best-in-class therapeutics. By incorporating proprietary structural modifications into miRNA therapeutics, the Groove Biopharma technology platform presents promising potential for treating a wide range of diseases, including cancer, fibrosis, and infectious disease.

Oncofactor is a Seattle, Washington-based developer of cancer therapeutics that disrupt signaling pathways between tumors and the immune system.

Mirador Biomedical is a company focused on developing and manufacturing innovative physiological pressure measurement devices. By collaborating with experienced medical professionals and scientists, the company aims to create cost-effective solutions that enhance the safety and accuracy of various medical procedures. Their product offerings include devices designed for compass vascular access, lumbar puncture, compartment pressure measurement, thoracentesis, and vascular access lock applications. Through these advancements, Mirador Biomedical seeks to provide vital physiological feedback, helping to reduce doubt and uncertainty during common medical interventions.

Nimbic is a provider of cloud-based electronic design automation (EDA) solutions specializing in electromagnetic integrity for the microelectronics industry. Headquartered in Mountain View, California, the company offers services that address challenges related to signal integrity, power integrity, and electromagnetic interference across various design domains, including microprocessors, FPGAs, memory, wireless RF systems, and high-speed channels. Nimbic's nCloud solution enables efficient chip-package-system co-design, significantly reducing time-to-market and costs for its clients. The company's advanced technology delivers high-capacity, rapid 3D simulations throughout the entire design cycle, maintaining exceptional accuracy and performance. Nimbic serves a global clientele that includes notable companies such as Texas Instruments, Renesas, Toshiba, Tabula, and Panasonic.

Mirador Biomedical is a company focused on developing and manufacturing innovative physiological pressure measurement devices. By collaborating with experienced medical professionals and scientists, the company aims to create cost-effective solutions that enhance the safety and accuracy of various medical procedures. Their product offerings include devices designed for compass vascular access, lumbar puncture, compartment pressure measurement, thoracentesis, and vascular access lock applications. Through these advancements, Mirador Biomedical seeks to provide vital physiological feedback, helping to reduce doubt and uncertainty during common medical interventions.

Uptake Medical specializes in developing innovative medical technologies aimed at treating lung diseases. The company's flagship product, InterVapor™, is an endoscopic lung volume reduction therapy designed specifically for individuals with severe emphysema. This unique approach leverages the body’s natural healing processes and does not introduce any foreign materials into the lungs. Clinical studies have shown that InterVapor™ can lead to significant improvements in patients' breathing function, exercise capacity, and overall quality of life.

Groove Biopharma focuses on the generation of novel microRNA (miRNA) therapeutics with improved properties, including higher potency and enhanced pharmacodynamic activity. Endogenous microRNAs (miRNAs) are involved in extensive regulatory networks for many target genes and pathways. Groove Biopharma’s core technology addresses a new avenue of nucleotide therapeutic drug discovery via modulation of cellular miRNA. Using exclusive technology, Groove Biopharma is generating a series of lead candidates with the potential to be best-in-class therapeutics. By incorporating proprietary structural modifications into miRNA therapeutics, the Groove Biopharma technology platform presents promising potential for treating a wide range of diseases, including cancer, fibrosis, and infectious disease.

Skytap, Inc. specializes in providing cloud-based development and testing environments aimed at migrating and modernizing enterprise applications globally. The company's primary offering, Skytap Cloud, allows for self-service access to production-like environments, facilitating more frequent code testing for development and testing teams. Skytap’s platform supports organizations in transitioning to modern software delivery methods by enabling the rapid migration of traditional workloads to the cloud and fostering the adoption of agile and DevOps practices. This approach helps businesses enhance their application development efficiency and integrate new cloud architectures. Additionally, Skytap provides a range of services including cloud migration, application modernization, training, and strategic consulting. Founded in 2006 and headquartered in Seattle, Washington, Skytap also maintains locations in Toronto, Canada, and London, United Kingdom.

Arzeda Corporation is a synthetic biology company based in Seattle, Washington, that specializes in the development and manufacture of proteins and enzymes for various applications, including pharmaceuticals, polymers, and industrial chemicals. Founded in 2008, Arzeda utilizes advanced technology that combines physics-based protein design with artificial intelligence algorithms to create and validate new designer proteins and enzymes. The company aims to provide innovative solutions that offer competitive performance, cost efficiency, and sustainability, addressing the needs of clients in diverse industries.

Corensic is a software company that specializes in providing quality tools designed to enhance the reliability of applications in multi-core environments. Founded in late 2008, and initially known as PetraVM, the company aims to assist developers and IT organizations in building higher quality software. Its flagship product, Jinx, is a tool that helps improve application performance by intentionally exposing hard-to-find concurrency bugs during the debugging process. Corensic's offerings include a visual studio extension and a command-line utility that enable developers and testers to detect and resolve catastrophic concurrency issues in both Windows and Linux applications. Backed by investors such as Madrona Ventures and the Washington Research Foundation, Corensic is committed to supporting the multi-core revolution in software development.

Nimbic is a provider of cloud-based electronic design automation (EDA) solutions specializing in electromagnetic integrity for the microelectronics industry. Headquartered in Mountain View, California, the company offers services that address challenges related to signal integrity, power integrity, and electromagnetic interference across various design domains, including microprocessors, FPGAs, memory, wireless RF systems, and high-speed channels. Nimbic's nCloud solution enables efficient chip-package-system co-design, significantly reducing time-to-market and costs for its clients. The company's advanced technology delivers high-capacity, rapid 3D simulations throughout the entire design cycle, maintaining exceptional accuracy and performance. Nimbic serves a global clientele that includes notable companies such as Texas Instruments, Renesas, Toshiba, Tabula, and Panasonic.

GlobeImmune, Inc. is a biopharmaceutical company based in Louisville, Colorado, dedicated to developing therapeutic products for cancer and infectious diseases through its proprietary Tarmogen platform. The company’s pipeline includes GS-4774, currently in Phase 2 trials for hepatitis B virus treatment, and various candidates targeting cancer, such as GI-6207 for medullary thyroid cancer, GI-6301 for tumors expressing the brachyury protein, and GI-4000 for resected pancreatic cancer. Additionally, GlobeImmune is advancing several candidates for infectious diseases, including GI-19000 for tuberculosis, GI-2010 for HIV, and GI-18000 for hepatitis D virus, currently in preclinical stages. The Tarmogen platform also includes products designed to address challenges in cancer therapy, such as preventing the emergence of mutated escape variants. The company has established strategic collaborations with Gilead Sciences and Celgene Corporation. Originally founded as Ceres Pharmaceuticals in 1995, GlobeImmune changed its name in 2001 to reflect its focus on innovative immunotherapy solutions.

Hyperion Therapeutics, Inc. is a biopharmaceutical company based in Brisbane, California, focused on developing and commercializing therapies for orphan diseases. The company specializes in treatments for urea cycle disorders (UCD), offering products such as RAVICTI, a nitrogen-binding agent used for the chronic management of UCD in both adults and pediatric patients. In addition to RAVICTI, Hyperion provides BUPHENYL and AMMONAPS for the treatment of specific UCD subtypes. The company is also exploring the application of glycerol phenylbutyrate, the active ingredient in RAVICTI, for the treatment of hepatic encephalopathy. Founded in 2006, Hyperion Therapeutics aims to address the needs of underserved patient populations through its innovative therapeutic developments.

Accelerator Corporation, founded in 2003 and based in Seattle, Washington, is a venture capital firm that specializes in early-stage investments in biotechnology companies. The firm primarily invests up to $2 million in emerging growth and start-up ventures, focusing on identifying, evaluating, financing, and managing groundbreaking life sciences opportunities. Accelerator does not participate in subsequent financing rounds and typically maintains its investments for 12 to 24 months. The firm has developed a robust pipeline of deal flow through partnerships with top-tier investors and research institutions, providing access to state-of-the-art facilities and expertise in scientific and technical support. Over the past five years, Accelerator has invested in nine companies, three of which successfully raised follow-on financing exceeding $114 million. In total, Accelerator's portfolio companies have garnered over $143.5 million in initial and follow-on funding, supported by an additional commitment of $22.5 million from investors to further pursue innovative biotechnology opportunities. Through its unique resources and collaborations, Accelerator is positioned to streamline the development and commercialization of novel technologies in the biotechnology sector.

Skytap, Inc. specializes in providing cloud-based development and testing environments aimed at migrating and modernizing enterprise applications globally. The company's primary offering, Skytap Cloud, allows for self-service access to production-like environments, facilitating more frequent code testing for development and testing teams. Skytap’s platform supports organizations in transitioning to modern software delivery methods by enabling the rapid migration of traditional workloads to the cloud and fostering the adoption of agile and DevOps practices. This approach helps businesses enhance their application development efficiency and integrate new cloud architectures. Additionally, Skytap provides a range of services including cloud migration, application modernization, training, and strategic consulting. Founded in 2006 and headquartered in Seattle, Washington, Skytap also maintains locations in Toronto, Canada, and London, United Kingdom.

HaloSource Corporation is a clean water technology company that focuses on developing and manufacturing innovative drinking water treatment solutions for global markets. Established in 2017 and headquartered in Bothell, Washington, the company leverages proprietary polymer chemistries to create a range of products aimed at improving water quality. Its offerings include gravity-based devices like the HaloPure disinfecting pitchers and associated cartridges, as well as pressurized devices such as bacteriostatic water cartridges and ceramic candle inserts. The HaloPure technology is recognized for its high international certifications, including registration with the US EPA, and serves over 10 million consumers worldwide. Additionally, HaloSource is expanding its product line to include lead removal media and is actively engaged in partnerships with trusted brands to further enhance its market presence. The company is well-positioned to capitalize on opportunities in the residential water treatment sector, supported by a robust pipeline of new products and strong regulatory compliance.

Omeros Corporation is a Seattle-based biopharmaceutical company that focuses on discovering, developing, and commercializing small-molecule and protein therapeutics targeting inflammation, complement-mediated diseases, and disorders of the central nervous system. The company offers OMIDRIA, a product used during cataract surgery in the United States. Omeros is advancing several clinical programs, including narsoplimab, which is in Phase III trials for conditions such as hematopoietic stem-cell transplant-associated thrombotic microangiopathy and immunoglobulin A nephropathy, as well as Phase II trials for lupus nephritis. Other key programs include OMS405, targeting opioid and nicotine addiction, and OMS527, aimed at treating addiction and movement disorders. The company's preclinical pipeline includes compounds addressing various conditions, such as paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders. Founded in 1994, Omeros is dedicated to addressing both large-market and orphan indications through innovative therapeutic approaches.

Targeted Growth, Inc. is a crop biotechnology company specializing in the development of technologies aimed at enhancing seed size and yield for the agricultural and biofuel sectors. Established in 1998 and headquartered in Seattle, Washington, with additional laboratories in the United States and Canada, the company focuses on developing high-yield and quality-improved food and energy crops such as canola, soybean, sugarcorn, and camelina. By increasing the productivity of these crops, Targeted Growth supports farmers in cultivating raw materials essential for the production of renewable fuels, including ethanol and biodiesel. Through its innovative approaches, the company contributes to advancements in sustainable agriculture and energy production.

Farecast is a fare-prediction startup founded in 2003 that helps travelers decide whether to purchase airline tickets or wait for potentially lower fares. The company utilizes analysis of 175 billion points of historical airfare data to provide intelligent predictions, claiming a success rate of 70-75% in forecasting price trends up to a week in advance. Farecast distinguishes itself from competitors by being the only service that offers these predictive insights. Additionally, the platform has expanded its offerings to include hotel deals, displaying results from various travel search sites on a map, which highlights pricing information. This allows users to quickly identify overpriced hotels, marked in blue, and attractively priced options, marked in red, ultimately helping travelers save money on their travel expenses.

Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutic antibodies to improve treatment for migraine patients in the United States, Australia, and Ireland. The company's lead candidate, eptinezumab, is a monoclonal antibody targeting calcitonin gene-related peptide, currently in late-stage clinical development for migraine prevention. Alder is also developing ALD1910, a preclinical monoclonal antibody aimed at inhibiting pituitary adenylate cyclase-activating polypeptide-38 for similar purposes, and Clazakizumab, which targets the pro-inflammatory cytokine interleukin-6 and has completed two Phase 2b trials. In addition to its product development efforts, Alder engages in strategic collaborations, notably with CSL Limited for advancing clazakizumab as a treatment for solid organ transplant rejection. Incorporated in 2002 and headquartered in Bothell, Washington, Alder operates primarily in the United States, where it generates most of its revenue.

VLST Corporation is a privately held biotechnology company that has developed a novel and streamlined approach to speed the development of effective therapeutics for the treatment of inflammatory and autoimmune diseases. The VLST platform uses novel bioinformatics and state-of-the-art proteomics, to identify viral genes whose protein products function as immunomodulatory agents. The resulting product candidates will be either human homologues to these virulence factors or monoclonal antibodies that mimic the function of the virulence gene products. This approach allows for the efficient identification of high quality, pre-validated drug targets for the treatment of autoimmune and inflammatory disorders. The Company's technology has identified potential product candidates for the treatment of disorders such as multiple sclerosis, lupus, psoriasis, rheumatoid arthritis and diabetes.

Targeted Growth, Inc. is a crop biotechnology company specializing in the development of technologies aimed at enhancing seed size and yield for the agricultural and biofuel sectors. Established in 1998 and headquartered in Seattle, Washington, with additional laboratories in the United States and Canada, the company focuses on developing high-yield and quality-improved food and energy crops such as canola, soybean, sugarcorn, and camelina. By increasing the productivity of these crops, Targeted Growth supports farmers in cultivating raw materials essential for the production of renewable fuels, including ethanol and biodiesel. Through its innovative approaches, the company contributes to advancements in sustainable agriculture and energy production.

Uptake Medical specializes in developing innovative medical technologies aimed at treating lung diseases. The company's flagship product, InterVapor™, is an endoscopic lung volume reduction therapy designed specifically for individuals with severe emphysema. This unique approach leverages the body’s natural healing processes and does not introduce any foreign materials into the lungs. Clinical studies have shown that InterVapor™ can lead to significant improvements in patients' breathing function, exercise capacity, and overall quality of life.

Teranode develops software and services aimed at enhancing research and development decision-making in the life sciences sector. The company's platform facilitates real-time business intelligence by integrating structured and unstructured data from various internal and external sources. This technology automates experiment workflows, manages biological data, and provides tailored data views to improve product life cycles. Additionally, Teranode’s software aids in compliance by automatically reviewing internal documents to identify and rectify deviations from regulatory policies. Overall, Teranode's solutions support executives and researchers by streamlining collaboration and laboratory automation, enabling them to access critical insights and effectively manage actions and alerts relevant to their work.

Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutic antibodies to improve treatment for migraine patients in the United States, Australia, and Ireland. The company's lead candidate, eptinezumab, is a monoclonal antibody targeting calcitonin gene-related peptide, currently in late-stage clinical development for migraine prevention. Alder is also developing ALD1910, a preclinical monoclonal antibody aimed at inhibiting pituitary adenylate cyclase-activating polypeptide-38 for similar purposes, and Clazakizumab, which targets the pro-inflammatory cytokine interleukin-6 and has completed two Phase 2b trials. In addition to its product development efforts, Alder engages in strategic collaborations, notably with CSL Limited for advancing clazakizumab as a treatment for solid organ transplant rejection. Incorporated in 2002 and headquartered in Bothell, Washington, Alder operates primarily in the United States, where it generates most of its revenue.

Farecast is a fare-prediction startup founded in 2003 that helps travelers decide whether to purchase airline tickets or wait for potentially lower fares. The company utilizes analysis of 175 billion points of historical airfare data to provide intelligent predictions, claiming a success rate of 70-75% in forecasting price trends up to a week in advance. Farecast distinguishes itself from competitors by being the only service that offers these predictive insights. Additionally, the platform has expanded its offerings to include hotel deals, displaying results from various travel search sites on a map, which highlights pricing information. This allows users to quickly identify overpriced hotels, marked in blue, and attractively priced options, marked in red, ultimately helping travelers save money on their travel expenses.

In the spring of 2002, Vanson, Inc. and HaloSource Corp. merged to form Vanson HaloSource, Inc. in order to expand opportunities for product commercialization by capitalizing on manufacturing facilities, distribution channels and intellectual property. Vanson’s cGMP certified manufacturing facility, located in Western Washington accommodates the production of most of Vanson HaloSource's products. The management team and a talented pool of chemists, biochemists and microbiologists are working together to create and expand the Company’s broad spectrum of applications. Today the Company holds dozens of patents and patents pending on a broad range of products that are distributed to the pool and spa, wastewater treatment, and biomedical industries. The Company has a substantial pipeline of proprietary new products in research and development, and a growing number of strategic alliances with prestigious companies to manufacture and market value-added chitin/chitosan-based and antimicrobial products.

Farecast is a fare-prediction startup founded in 2003 that helps travelers decide whether to purchase airline tickets or wait for potentially lower fares. The company utilizes analysis of 175 billion points of historical airfare data to provide intelligent predictions, claiming a success rate of 70-75% in forecasting price trends up to a week in advance. Farecast distinguishes itself from competitors by being the only service that offers these predictive insights. Additionally, the platform has expanded its offerings to include hotel deals, displaying results from various travel search sites on a map, which highlights pricing information. This allows users to quickly identify overpriced hotels, marked in blue, and attractively priced options, marked in red, ultimately helping travelers save money on their travel expenses.

Corus Pharma is a biotech and specialty drug company that focuses on respiratory and infectious diseases. In other words, it is a development stage biopharmaceutical company that focuses on the development and commercialization of novel applications and formulations of known therapeutics to treat severe respiratory diseases. The products of the company are Corus 1020 and 1030. Corus 1020 is designed to treat respiratory infections in cystic fibrosis patients, using an inhalable form of an antibiotic called aztreonam. Corus 1030 is inhaled lidocaine for the treatment of patients suffering from the severe persistent forms of asthma. Corus Pharma is a U.S.-based company that was founded in 2001 and the company was acquired by Gilead Sciences on October 22, 2006.

Noting the growing trends in group travel, [Expedia](http://www.crunchbase.com/organization/expedia) and [Microsoft](http://www.crunchbase.com/organization/microsoft) vets founded TripHub in 2005. Based on the philosophy that "planning should be as fun as the trip," TripHub provides users with many different ways to facilitate group travel. Recently, Triphub [teamed up](http://about.triphub.com/2006/01/plan-talk-among.html) with [Orbitz](http://www.orbitz.com) to provide a ["powered by Triphub"](http://about.triphub.com/partners/index.html)group travel option. They are funded by Madrona Venture Group and other private investors. ###TripHub entered the deadpool on August 25, 2008.###